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Background: In patients with acute heart failure (AHF), the development of worsening renal function with
appropriate decongestion is thought to be a benign functional change and not associated with poor prognosis. We
investigated whether the benefit of decongestion outweighs the risk of concurrent kidney tubular damage and
leads to better outcomes.
Methods: We retrospectively analyzed data from the AKINESIS study, which enrolled AHF patients requiring
intravenous diuretic therapy. Urine neutrophil gelatinase-associated lipocalin (uNGAL) and B-type natriuretic
peptide (BNP) were serially measured during the hospitalization. Decongestion was defined as ≥30% BNP
decrease at discharge compared to admission. Univariable and multivariable Cox models were assessed for oneyear mortality.
Results: Among 736 patients, 53% had ≥30% BNP decrease at discharge. Levels of uNGAL and BNP at each
collection time point had positive but weak correlations (r ≤ 0.133). Patients without decongestion and with
higher discharge uNGAL values had worse one-year mortality, while those with decongestion had better
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outcomes regardless of uNGAL values (p for interaction 0.018). This interaction was also significant when the
change in BNP was analyzed as a continuous variable (p < 0.001). Although higher peak and discharge uNGAL
were associated with mortality in univariable analysis, only ≥30% BNP decrease was a significant predictor after
multivariable adjustment.
Conclusions: Among AHF patients treated with diuretic therapy, decongestion was generally not associated with
kidney tubular damage assessed by uNGAL. Kidney tubular damage with adequate decongestion does not impact
outcomes; however, kidney injury without adequate decongestion is associated with a worse prognosis.

1. Introduction

consent. Patients were enrolled if they had findings consistent with HF
and had received or planned intravenous diuretic therapy. Exclusion
criteria were (1) acute coronary syndrome, (2) dialysis-dependence or
planned initiation during the hospitalization, (3) major organ trans
plantation, (4) enrolment in a drug treatment study within the past 30
days or prior enrolment in this study, and (5) pregnant or vulnerable
population determined by an institutional review board. In the current
analysis, we excluded 70 patients discharged from the emergency
department, 43 patients without serial BNP measurements, and 78 pa
tients without uNGAL measurement during hospitalization, leaving 736
patients for analysis.

Heart failure (HF) is a clinical syndrome of cardiac dysfunction often
resulting in systemic organ dysfunction and compounded by concomi
tant comorbidities. Because of a close interaction between the heart and
kidney, chronic kidney disease is one of the most common comorbidities
in HF, and an acute deterioration in renal function is often observed in
the setting of acutely decompensated HF [1–3]. This is termed wors
ening renal function (WRF), which is usually defined by an increase in
creatinine or a decrease in estimate glomerular filtration rate (eGFR).
Originally thought to be an adverse event, it is now well-described that
the clinical significance of WRF depends on the context in which it oc
curs, with no known adverse consequences seen when WRF occurs with
appropriate decongestion [4–8]. These findings suggest the benefit of
decongestion may outweigh any potential harms of WRF.
However, creatinine is a marker of the glomerular filtration function,
and several studies have reported a dissociation between WRF and ele
vations in biomarkers that evaluate kidney damage at the level of the
tubule [9–12]. Therefore, the presence of kidney tubular injury could be
overlooked when assessed only by creatinine or eGFR, and the direct
relationships between decongestion and kidney tubular damage and
their prognostic implications for clinical outcomes have not been well
assessed. It remains uncertain whether the development of kidney
tubular damage offsets the benefits of decongestion. Conversely, tubular
damage with refractory congestion may identify a higher risk cohort
suffering from a more severe form of cardio-renal syndrome.
The Acute Kidney Injury Neutrophil gelatinase-associated lipocalin
(NGAL) Evaluation of Symptomatic heart faIlure Study (AKINESIS) was
a prospective observational study of acute HF (AHF) patients who
required intravenous diuretic therapy [13]. We have recently demon
strated the clinical implications of WRF can be risk stratified by changes
in B-type natriuretic peptide (BNP), which is a well-established
biomarker of congestion [8,14]. BNP has been shown to decrease
rapidly, corresponding to decongestive therapy and decreasing cardiac
pressures, and its decrease is a strong predictor of better outcomes in
AHF [8,15–17]. In this sub-analysis, we evaluated whether the prog
nostic implications of congestion status, as assessed by change in BNP,
interact with an elevation in urine NGAL (uNGAL), a kidney tubular
damage biomarker. NGAL is from the lipocalin family of proteins and is
released from kidney tubular cells following injuries under stress con
ditions such as contrast-induced nephropathy, cardiac surgery, and
critical illness [18–20]. We investigated 1) the relationship between
decongestion and kidney tubular damage during the treatment for AHF,
2) the prognostic value of uNGAL for in-hospital and one-year mortality
and one-year HF readmission, and 3) whether prognostication with
uNGAL can be further discriminated by BNP decrease.

2.2. Biomarker assessment
Specimens for uNGAL and BNP measurement were collected at sixtime points of hospitalization; on admission; 4 h later; hospital days 1,
2, and 3 and day of discharge or anticipated discharge. Serum creatinine
was measured each day during hospitalization. Details of sample anal
ysis have been previously published [8,21]. Levels of uNGAL were
indexed to urine creatinine to account for urine dilution. Decongestion
was defined as a ≥ 30% BNP decrease at the last available value (either
at discharge or the last measured) compared to the admission value
based on prior literatures and our previous report showing discrimina
tion for prognosis in WRF at this cut-off [8,17,22,23]. As a sensitivity
analysis, change in BNP was also analyzed as a continuous variable as
the ratio of discharge to admission values.
2.3. Outcomes
The clinical outcomes were in-hospital and one-year mortality and
one-year HF readmission. The one-year outcomes were determined by
phone follow-up or medical record review. Follow up was available in
>98% of participants.
2.4. Statistical analysis
Continuous variables were described as means with standard de
viations (SD), and categorical variables were described as counts and
percentages. Non-normally distributed data were described as medians
and interquartile ranges (IQR). Patient characteristics were compared by
tertiles of discharge uNGAL values with ANOVA, Kruskal-Wallis and
Chi-square tests as appropriate. Patient characteristics by ≥30% or <
30% BNP decrease were also assessed by t-test, Mann–Whitney and Chisquare tests as appropriate. Levels of uNGAL and eGFR, and the inci
dence of WRF were also compared in patients with ≥30% and < 30%
BNP decrease. WRF was defined by the criteria initially used in AKI
NESIS; sustained increase (more than two consecutive days) in creati
nine of 0.5 mg/dl or ≥ 50% above first value or initiation of acute renalreplacement therapy, within the first 5 days of hospitalization. Corre
lations between uNGAL and BNP were evaluated by Spearman’s rank
correlation coefficient. For the assessment of the clinical events, levels of
uNGAL were examined by admission and peak values for in-hospital
mortality, and admission, peak and discharge values for one-year mor
tality and HF readmission. When a patient lacked a measurement at
discharge, the last measured value was substituted. Because of the
relatively small number of in-hospital deaths (24 patients, 3%), only

2. Methods
2.1. Study population
We retrospectively analyzed the AKINESIS study, which was a pro
spective, international, multicenter cohort study of AHF patients,
enrolling 927 patients at 16 sites in the United States and Europe from
January 2011 through September 2013 [13]. The study was approved
by institutional review boards at each site and all patients gave written
2
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bivariable logistic regression analysis with uNGAL and BNP decrease
was performed. Kaplan-Meier, log-rank and Cox regression analysis
were used for one-year mortality and HF readmission. uNGAL was
examined both as tertiles and as a continuous variable using restricted
cubic splines with 3 knots for an interaction with BNP change during
hospitalization. An interaction analysis was also performed with eGFR
values instead of uNGAL. The change (delta) between the lowest values
during hospitalization and admission values, and delta between
discharge and admission values were evaluated. In multivariable Cox
regression analysis, decreased BNP and uNGAL were adjusted for age,
Black race, history of chronic obstructive pulmonary disease, oedema,
systolic blood pressure, heart rate, sodium, hemoglobin, blood urea ni
trogen (BUN) and high sensitivity cardiac troponin I based on prior
studies [24–27]. Multicollinearity was assessed by variance inflation
factor (VIF). We also evaluated net reclassification improvement (NRI)
and integrated discrimination improvement (IDI) when uNGAL values
were added to the model composed of other factors in the multivariable
analysis.Levels of uNGAL, cardiac troponin and relative change in BNP
were log-2 transformed. All statistical analyses were performed using R
version 4.0.3.

Table 1
Baseline characteristics of patients by tertile of uNGAL at hospital discharge.

Age (years), mean (SD)
Caucasian, n (%)
Male sex, n (%)
History of CAD, n (%)
History of hypertension,
n (%)
History of
hyperlipidemia, n (%)
History of diabetes
mellitus, n (%)
History of COPD, n (%)
History of CKD, n (%)
Tobacco use, n (%)
ACE-I or ARB, n (%)
β-blocker, n (%)
Diuretics, n (%)
Oedema, n (%)
JVD present, n (%)
Rales present, n (%)
Systolic BP (mmHg),
mean (SD)
Heart rate (bpm), mean
(SD)
Sodium (mEq/l), mean
(SD)
Hemoglobin (g/dl),
mean (SD)
BUN (mg/dl), median
[IQR]
Creatinine (mg/dl),
median [IQR]
eGFR (ml/min/1.73
m2), mean (SD)
BNP (ng/L), median
[IQR]
hscTnI (ng/l) (median
[IQR])
uNGAL (ug/g) (median
[IQR])
Renal replacement
therapy, n (%)
Inotrope use, n (%)
Mechanical ventilation,
n (%)

3. Results
3.1. Patient characteristics by discharge uNGAL values
Among 736 patients, the mean age was 69 ± 14 years, 64% were
male, 47% had coronary artery disease, 44% had diabetes, and 26%
reported a history of chronic kidney disease (CKD). The median creati
nine was 1.20 mg/dl (IQR 0.94–1.60 mg/dl), median eGFR was 57 ml/
min/1.73m2 (IQR 40–78 ml/min/1.73m2), and median BNP was 569
ng/L (IQR 233–1108 ng/L) on admission. Median length of hospital stay
was 6 days (IQR 4–10 days). Admission values of uNGAL were missing in
9 patients. The discharge sample was collected at the day of discharge in
56%, within 3 days before discharge in 24% and more the three days in
20% of patients. Median admission, peak and discharge levels of uNGAL
were 27.2 μg/g (IQR 13.1–68.0 μg/g), 48.5 μg/g (IQR 22.5–128.1 μg/g)
and 29.0 μg/g (IQR 13.3–76.1 μg/g), respectively. Patients with higher
levels of discharge uNGAL were older, more likely to be Caucasian and
female, more frequently had a history of CKD, and had higher admission
BUN and creatinine (Table 1). They were less often treated with
angiotensin converting enzyme inhibitors or angiotensin receptor
blockers and had lower levels of admission hemoglobin and eGFR. Pa
tients with higher discharge uNGAL more often received renal replace
ment therapy during hospitalization, while use of inotropes and
mechanical ventilation were not associated with discharge uNGAL
levels.

Tertile 1

Tertile 2

Tertile 3

p-value

≤17.6 μg/
g

17.7 μg/g to
50.8 μg/g

≥50.9 μg/g

n = 245

n = 246

n = 245

64 (13)
145 (59)
205 (84)
112 (46)
191 (78)

71 (13)
164 (67)
155 (63)
128 (52)
203 (83)

71 (14)
167 (68)
112 (46)
104 (42)
198 (81)

<0.001
0.084
<0.001
0.096
0.437

126 (51)

125 (51)

124 (51)

0.982

96 (39)

115 (47)

114 (47)

0.158

59 (24)
48 (20)
46 (19)
83 (34)
181 (74)
171 (70)
179 (73)
59 (24)
97 (40)
140 (31)

76 (31)
59 (24)
39 (16)
91 (37)
173 (70)
180 (73)
183 (74)
71 (29)
107 (44)
141 (28)

54 (22)
83 (34)
27 (11)
62 (25)
174 (71)
169 (69)
191 (78)
67 (27)
116 (47)
140 (31)

0.063
0.001
0.054
0.016
0.651
0.557
0.431
0.474
0.223
0.797

89 (23)

88 (23)

85 (21)

0.121

138 (10)

139 (5)

138 (5)

0.461

12.5 (2.5)

11.6 (2.5)

11.0 (2.1)

<0.001

21.0 [15.0,
28.8]
1.13 [0.94,
1.41]
69 (29)

24.0 [17.0,
36.0]
1.17 [0.90,
1.50]
62 (27)

30.7 [20.7,
46.0]
1.38 [1.00,
2.04]
50 (25)

<0.001

498 [211,
1004]
25.3 [12.5,
54.8]
11.5 [7.0,
19.6]
2 (1)

628 [265,
1138]
27.8 [13.9,
64.4]
27.4 [16.9,
45.3]
2 (1)

629 [231,
1188]
24.3 [12.2,
57.2]
83.8 [41.5,
258.0]
11 (5)

0.07

19 (8)
24 (10)

23 (9)
16 (7)

25 (10)
19 (8)

0.633
0.399

<0.001
<0.001

0.502
<0.001
0.004

ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor
blocker; BNP, B-type natriuretic peptide; BP, blood pressure; BUN, blood urea
nitrogen; CAD, coronary artery disease; COPD, chronic obstructive pulmonary
disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate;
hscTnI, high sensitivity cardiac troponin I; IQR, interquartile range; JVD, jugular
venous distention; SD, standard deviation; uNGAL, urine neutrophil gelatinaseassociated lipocalin.

3.2. Patient characteristics by BNP decrease
At discharge, 388 patients (53%) had achieved a ≥ 30% decline in
BNP compared to admission. Patients with ≥30% BNP decrease were
younger, less likely to be Caucasian and less often have a history of CKD
(Supplemental Table 1). They had higher SBP, sodium and eGFR, and
lower BUN and creatinine on admission.There was a greater weight loss
in patients with a ≥ 30% BNP decrease compared to those with a < 30%
BNP decrease (− 1.4 kg [IQR − 3.7 to 0 kg] versus − 0.9 kg [IQR − 2.5 to
0.8 kg], p = 0.025) with greater average daily urine output (2064 ±
1121 ml/day versus 1840 ± 989 ml/day, p = 0.031) within the first 3
days of hospitalization. The average dose of loop diuretics within the
first 3 days of admission was not different between those with or without
≥30% BNP decrease (intravenous furosemide equivalent 58 mg/day
[IQR 40–105 mg/day] versus 60 mg/day [IQR 38–93 mg/day], p =
0.569). Among 417 patients (57%) with data of hematocrit at admission
and discharge, an elevation of discharge levels compared to admission
was observed in 36% in a ≥ 30% BNP decrease and 32% in a < 30% BNP
decrease (p = 0.380).

3.3. Association of BNP, uNGAL and eGFR
During the hospitalization, levels of uNGAL and BNP at each
collection time point had positive but weak correlations (r ≤ 0.133,
Supplemental Table 2), but this correlation was no longer significant by
time of discharge. When the correlation of uNGAL with BNP was
examined by individuals who achieved and did not achieve a ≥ 30%
BNP decrease, there was a significant correlation between uNGAL and
BNP levels in those with a < 30% BNP decrease but there was no cor
relation between uNGAL and BNP levels in those with a ≥ 30% BNP
decrease (Supplemental Table 2). Levels of admission, peak and
discharge uNGAL were not different between patients with a ≥ 30% BNP
decrease and a < 30% BNP decrease (admission values, 28.0 μg/g [IQR
13.6–67.0 μg/g] in ≥30% BNP decrease versus 25.7 μg/g [IQR
12.8–70.0 μg/g] in <30% BNP decrease, p = 0.527; peak values 48.8 μg/
3
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g [IQR 22.6–122.2 μg/g] versus 47.8 μg/g [IQR 21.9–129.5 μg/g], p =
0.799; and discharge values 38.3 μg/g [IQR 14.9–99.3 μg/g] versus
38.6 μg/g [IQR 14.0–108.7 μg/g], p = 0.882). eGFR was higher in pa
tients with ≥30% BNP decrease compared to those with <30% BNP
decrease at all time points (admission, 64 ± 29 ml/min/1.73 m2 versus
58 ± 27 ml/min/1.73 m2, p = 0.002; the lowest eGFR during hospi
talization 53 ± 25 ml/min/1.73 m2 versus 49 ± 25 ml/min/1.73 m2, p
= 0.03; hospital discharge, 61 ± 31 ml/min/1.73 m2 versus 56 ± 27
ml/min/1.73 m2, p = 0.039, for ≥30% BNP decrease versus <30% BNP
decrease, respectively). WRF occurred in 62 patients and its incidence
was not different between the groups (9% in ≥30% BNP decrease versus
8% in <30% BNP decrease, p = 0.629).

Table 2A
Logistic regression analysis for in-hospital mortality.
Univariable analysis

OR

95% CI

p-value

Admission uNGAL
Peak uNGAL
BNP decrease

1.19
1.27
0.08

0.99–1.43
1.06–1.53
0.02–0.33

0.078
0.013
< 0.001

Bivariable analysis

Adjusted OR

95% CI

p-value

Admission uNGAL
BNP decrease

1.2
0.07

0.99–1.46
0.02–0.32

0.065
< 0.001

Peak uNGAL
BNP decrease

1.31
0.07

1.07–1.6
0.02–0.32

0.009
< 0.001

3.4. In-hospital mortality
significantly associated with lower one-year mortality. No significant
multicollinearity was observed in the multivariable models (VIF ≤ 1.17
for model with admission uNGAL, ≤ 1.18 for peak uNGAL, ≤ 1.20 for
discharge uNGAL, Supplemental Table 3). Neither admission, peak nor
discharge uNGAL improved risk reclassification assessed by NRI and IDI
(Supplemental Table 4). When an interaction of eGFR changes and BNP
decrease for one-year mortality was assessed in the Cox models, no
significant interaction was observed (p for interaction ≥0.641 with
≥30% BNP decrease and ≥ 0.640 with ratio of BNP change). Regarding
one-year HF readmission, neither BNP decrease nor uNGAL values was
associated with its incidence in the Kapan Meier analysis (Supplemental
Fig. 1). No significant interaction was observed with BNP decrease and
uNGAL values for HF readmission in Cox analysis (p for interaction
≥0.624 with ≥30% BNP decrease and ≥ 0.222 with ratio of BNP
change). When these analysis were performed with eGFR instead of
uNGAL values, no significant interaction was observed for one-year HF
readmission (p for interaction ≥0.498 with ≥30% BNP decrease and ≥
0.232 with ratio of BNP change). In univariable and multivariable Cox
analysis, uNGAL and BNP decrease were not associated with HF read
mission (Table 2C). No significant multicollinearity was observed in the
multivariable models (VIF ≤ 1.30 for model with admission uNGAL, ≤
1.31 for peak uNGAL and ≤ 1.32 for discharge uNGAL, Supplemental
Table 3). Admission, peak or discharge uNGAL did not improve reclas
sification of risk for HF readmission assessed by NRI and IDI (Supple
mental Table 4).

In-hospital mortality was 3% (24 patients). Regardless of the uNGAL
tertile, patients with a ≥ 30% BNP decrease had lower in-hospital
mortality than patients with a < 30% BNP decrease. For patients with
a < 30% BNP decrease, a stepwise increase in mortality was seen with
higher tertiles of uNGAL with the highest in-hospital mortality observed
in patients with BNP < 30% and the highest uNGAL (Fig. 1A and B). In
logistic regression analysis, higher levels of peak uNGAL were signifi
cantly associated with in-hospital mortality in univariable and bivari
able models with BNP decrease (Table 2A).
3.5. One-year outcomes
During the one-year follow-up, 130 patients (18%) died and 146
(19%) patients were re-hospitalized due to HF. Overall, irrespective of
when uNGAL was measured (admission, peak or discharge), patients
with a < 30% BNP decrease had a higher one-year mortality than those
with a ≥ 30% BNP decrease for each tertile of uNGAL (Fig. 2A, B and C).
With respect to specific time points of uNGAL measurements, higher
tertiles of admission and peak uNGAL were associated with higher
mortality in patients with both a ≥ 30% and < 30% BNP decrease (p for
interaction = 0.758 and 0.389, Fig. 2A and B). However, higher tertiles
of discharge uNGAL predicted poor prognosis only in patients with
<30% BNP decrease but not in ≥30% decrease (p for interaction =
0.025, Fig. 2C). This finding was also observed when discharge uNGAL
was analyzed using restricted cubic spline analysis (Fig. 2D, p for
interaction = 0.018). This interaction was not affected whether change
in BNP was analyzed as a continuous variable (p < 0.001). These find
ings were not observed with admission and peak uNGAL (p for inter
action ≥0.273). In univariable Cox analysis, peak and discharge uNGAL
were associated with one-year mortality (Table 2B). However, in
multivariable analysis, uNGAL was no longer significantly associated
with one-year mortality; in contrast a ≥ 30% BNP decrease remained

4. Discussion
In hospitalized AHF patients treated with intravenous diuretic ther
apy, we found decongestion defined as a ≥ 30% BNP decrease was not
associated with an elevation in uNGAL. A decrease in BNP, but not
uNGAL, was an independent predictor of one-year mortality. Intrigu
ingly, higher levels of discharge uNGAL predicted poor prognosis only in

Fig. 1. In-hospital mortality by uNGAL and BNP decrease.
Patients with a ≥ 30% BNP decrease had lower in-hospital mortality in every strata of admission (Fig. 1A) and peak (1B) levels of uNGAL. Tertiles of uNGAL were ≤
16.5 μg/g, 16.6 μg/g to 48.0 μg/g, and ≥ 48.1 μg/g for admission and ≤ 29.5 μg/g, 29.6 μg/g to 85.0 μg/g, and ≥ 85.1 μg/g for peak values.
BNP, B-type natriuretic peptide; uNGAL, urine neutrophil gelatinase-associated lipocalin.
4
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Fig. 2. One-year mortality by uNGAL and BNP decrease. A. One-year mortality by admission uNGAL and BNP decrease. B. One-year mortality by peak uNGAL and
BNP decrease. C. One-year mortality by discharge uNGAL and BNP decrease. D. Hazard ratios of uNGAL for one-year mortality in patients with and without BNP
decrease.
Higher tertiles of admission and peak uNGAL were associated with higher mortality in patients with both ≥30% and < 30% BNP decrease at discharge or the last
value (p for interaction = 0.758 and 0.389, Fig. 2A and B). For discharge uNGAL, a ≥ 30% BNP decrease was associated with lower one-year mortality regardless of
uNGAL levels, while higher levels of discharge uNGAL predicated poor prognosis in patients with <30% BNP decrease (p for interaction = 0.025, Fig. 2C). This
finding was also observed when discharge uNGAL was analyzed using restricted cubic spline analysis (Fig. 2D, p for interaction = 0.018).
Tertiles of uNGAL were ≤ 16.5 μg/g, 16.6 μg/g to 48.0 μg/g, and ≥ 48.1 μg/g for admission, ≤29.5 μg/g, 29.6 μg/g to 85.0 μg/g, and ≥ 85.1 μg/g for peak, and ≤
17.6 μg/g, 17.7 μg/g to 51.1 μg/g, and ≥ 51.2 μg/g for discharge.
BNP, B-type natriuretic peptide; HR, hazard ratio; uNGAL, urine neutrophil gelatinase-associated lipocalin.

patients with a < 30% BNP decrease and patients with a ≥ 30% BNP
decrease had lower one-year mortality regardless of the levels of uNGAL.
This finding remained significant when the change in BNP was consid
ered as a continuous variable. These findings reinforce the importance of

achieving adequate decongestion in AHF regardless of kidney tubular
damage, but also caution about the presence of kidney tubular damage
with residual congestion at hospital discharge.
Numerous different pathophysiologic processes may contribute to
5
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Fig. 2. (continued).

kidney injury and dysfunction in AHF [1]. One of the most important
hemodynamic contributors is systemic congestion with elevated venous
pressure leading to renal congestion. Diuretics and vasodilators may also
contribute to drastic changes in volume status during AHF treatment,
leading to neurohormonal activation with impaired sodium and water
handling in the kidney. The effects of these deleterious processes are
primarily recognized by changes in creatinine, a measure of glomerular
filtration, and creatinine’s change is thought to be induced by kidney
tubular damage [2]. However, kidney dysfunction and injury can be
assessed both at the level of the glomerulus with changes in filtration, i.
e. changes in creatinine, and at the level of the tubule with novel bio
markers of injury [28]. While creatinine frequently rises in AHF, mul
tiple studies have offered evidence suggesting WRF during decongestion
therapy in AHF generally lacks kidney injury [9,11,13,21]. Among AHF
patients treated with aggressive diuretic therapy in the ROSE-AHF trial,
changes in serum creatinine and cystatin C were not correlated with

changes in tubular injury biomarkers, such as uNGAL, N-acetyl-β-dglycosaminidase, or kidney injury molecule-1 [9]. Our findings from
AKINESIS showed serum and uNGAL were not predictive of subsequent
WRF in hospitalized AHF patients [11,13,21]. While these studies in
general show a lack of kidney tubular damage with WRF in AHF,
whether decongestive therapy and kidney tubular damage are related
and whether decongestion or kidney tubular damage have prognostic
implications independent of changes in creatinine has not been fully
evaluated.
In the current analysis, we explored the relationship between kidney
tubular damage and decongestion assessed by a decrease in BNP. A
decrease in BNP was not accompanied by an increase in kidney tubular
damage, whereas higher levels of uNGAL were associated with higher
BNP levels at each collection time point except discharge. These positive
correlations could be due to kidney tubular damage from persistent
kidney congestion or underlying acute or chronic kidney damage
6
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injury biomarkers are actually associated with a better prognosis. The
ROSE-AHF trial reported an increase in all three kidney injury bio
markers after diuretic treatment was paradoxically associated with
improved 180-day survival [9]. In addition, patients with both elevated
kidney injury biomarkers and serum cystatin C had the lowest mortality.
Similar results were reported in an analysis of CARRESS-HF trial that
randomized AHF patients with pre-existing WRF to intensive volume
removal with pharmacological therapy or ultrafiltration [10]. Although
intensive volume removal induced further WRF and increases in renal
tubular injury biomarkers, these changes were also associated with a
higher incidence of hemoconcentration and a better recovery of creati
nine at 60 days. These findings suggest the benefits of decongestion
outweigh the risks not only of WRF, but also kidney tubular damage in
patients hospitalized with AHF.
Building on these studies, we showed even in patients who had more
severe kidney injury assessed by uNGAL at hospital discharge, their
prognosis was better when accompanied by adequate decongestion
assessed by a decrease in BNP. Inversely, higher levels of discharge
uNGAL were associated with higher one-year morality only in patients
without an adequate BNP decrease. These findings reinforce the
importance of achieving decongestion during hospitalization and sug
gest kidney tubular damage may be tolerable in these circumstances.
However, in the setting of inadequate decongestion, persistent kidney
tubular damage portends a worse prognosis. In this case, the inability to
adequately decongest may be a result of significant kidney tubular
damage leading to diuretic resistance. These results are in agreement
with our prior findings that WRF was not associated with poor prognosis
in AHF when patients achieve an appropriate decrease in BNP but when
there is an inadequate BNP decrease, WRF predicts a higher mortality
[8]. Therefore, clinicians may primarily focus on diuretic therapy to
accomplish decongestion even in the setting of concurrent kidney
tubular damage and WRF, but special attention should be given to pa
tients with residual congestion and kidney damage and/or dysfunction
who have significantly worse outcomes. Further research is needed to
determine best treatments to optimize congestion status and reduce
mortality in these higher risk patients.
In the current analysis, neither BNP decrease nor uNGAL values
predicted HF readmission within one-year follow up. HF readmission is
frequently difficult to predict because it is influenced not only by status
at discharge, but also by disease severity, post-discharge dietary choices,
fluid intake, adherence to oral medications, and social factors [33,34].
In addition, the recurrence of congestion after discharge is a more
important predictor of renal dysfunction and HF hospitalization than the
degree of congestion at discharge. These complexities in HF hospitali
zation may explain why BNP decrease and uNGAL were not associated
with HF readmission in this study.

Table 2B
Cox regression analysis for one-year mortality.
Univariable analysis

HR

95% CI

p-value

Admission uNGAL
Peak uNGAL
Discharge uNGAL
BNP decrease

1.06
1.10
1.14
0.42

0.98–1.16
1.01–1.20
1.05–1.23
0.29–0.60

0.148
0.021
0.002
< 0.001

Multivariable analysis

Adjusted HR

95% CI

p-value

Admission uNGAL
BNP decrease

1.02
0.55

0.93–1.12
0.37–0.82

0.632
0.003

Peak uNGAL
BNP decrease

1.05
0.56

0.96–1.15
0.38–0.82

0.305
0.003

Discharge uNGAL
BNP decrease

1.07
0.55

0.97–1.18
0.37–0.80

0.164
0.002

Table 2C
Cox regression analysis for one-year HF rehospitalization.
Univariable analysis

HR

95% CI

p-value

Admission uNGAL
Peak uNGAL
Discharge uNGAL
BNP decrease

1.00
0.98
0.98
1.00

0.92–1.09
0.90–1.06
0.90–1.07
0.72–1.38

0.977
0.592
0.633
0.976

Multivariable analysis

Adjusted HR

95% CI

p-value

Admission uNGAL
BNP decrease

1.00
1.10

0.91–1.08
0.77–1.55

0.837
0.607

Peak uNGAL
BNP decrease

0.96
1.12

0.88–1.05
0.79–1.58

0.399
0.530

Discharge uNGAL
BNP decrease

0.96
1.12

0.88–1.06
0.79–1.59

0.422
0.529

Levels of uNGAL were log-2 transformed. In multivariable Cox regression
analysis, BNP decrease and uNGAL were adjusted for age, African American
Race, history of chronic obstructive pulmonary disease, oedema, systolic blood
pressure, heart rate, sodium, hemoglobin, blood urea nitrogen and high sensi
tivity cardiac troponin I.
BNP, B-type natriuretic peptide; uNGAL, urine neutrophil gelatinase-associated
lipocalin.

limiting diuretic responsiveness and thus the ability to effectively
decongest a patient [29]. Any combination of these phenomena might
explain the positive correlations between uNGAL and BNP found in
patients with a < 30% BNP decrease but not those with a ≥ 30% BNP
decrease. These findings suggest that kidney tubular injury without
effective decongestion identifies a high-risk population of patients with
cardio-renal syndrome that cannot be ignored.
Prior studies have reported variable prognostic implications of kid
ney tubular damage biomarkers in AHF. Several studies have reported
an elevated uNGAL at presentation predicts mortality, HF hospitaliza
tion and other cardiovascular events [30,31]. However, in AKINESIS,
which is one of the largest cohorts of AHF patients specifically designed
to assess the clinical implication of NGAL, we reported that neither
admission nor peak uNGAL predicted a composite outcome of death,
renal replacement therapy, HF readmission or an urgent HF related
outpatient visit within 30 and 60 days from study enrolment [32].
Similarly, in our current analysis, admission, peak and discharge levels
of uNGAL were not associated with one-year mortality after confound
ing factors were considered. Although higher peak uNGAL values were
associated with in-hospital mortality, this needs to be interpreted
cautiously, considering the limited number of in-hospital deaths,
allowing only bivariable analysis with BNP change to be performed.
Intriguingly, two recent studies have reported that elevated kidney

4.1. Limitations
This is a post-hoc analysis of a prospective cohort study. Identified or
unidentified confounders may have influenced the result. Multivariable
analysis was not performed for in-hospital mortality because of the
limited number of events. Last measured value of uNGAL was collected
at more than 3 days before hospital discharge in 20%, which may not
reflect treatment in this subset of patients after the final collection of the
specimen. While decongestion was evaluated by BNP decrease, other
methods such as physical examination, echocardiographic findings or
direct hemodynamic assessment with heart catheterization may also be
considered. Unfortunately, this data was not available in the AKINESIS.
However, greater weight loss and urine output in the BNP decrease
group suggest greater volume depletion in these patients. While the
incidence of hemoconcentration was numerically higher in those with
BNP decrease, this was not statistically significant possibly due to the
limited number of hemoglobin measurements at hospital discharge.
Kidney injury was only evaluated by uNGAL and other biomarkers were
not measured. While uNGAL may be useful for risk stratification
7
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especially in patients without adequate decongestion, its routine use in
AHF is not currently recommended.
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5. Conclusions
Among AHF patients treated with diuretic therapy, decongestion was
not associated with kidney tubular damage as assessed by uNGAL. The
presence of kidney tubular damage at hospital discharge was not asso
ciated with increased mortality at one year when accompanied by
adequate decongestion. However, with residual congestion, AHF pa
tients with the kidney tubular damage have a worse one-year survival.
These findings emphasize the importance of achieving decongestion in
AHF even if this approach is associated with kidney tubular damage, but
also recognizing that AHF patients with residual congestion and kidney
tubular damage are a high-risk population with higher one year
mortality.
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